| Original language | English (US) |
|---|---|
| Pages (from-to) | e177 |
| Journal | Journal of the American College of Cardiology |
| Volume | 79 |
| Issue number | 7 |
| DOIs | |
| State | Published - Feb 22 2022 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Reply : Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All? / Chin, Kelly M.; Doelberg, Martin; Martin, Nicolas et al.
In: Journal of the American College of Cardiology, Vol. 79, No. 7, 22.02.2022, p. e177.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?
AU - Chin, Kelly M.
AU - Doelberg, Martin
AU - Martin, Nicolas
AU - Perchenet, Loïc
AU - Galie, Nazzareno
N1 - Funding Information: This study was funded by Actelion Pharmaceuticals, Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Medical writing support was provided by Laura Corbett of eluSCIdate Ltd (Meggen, Switzerland) and was funded by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Dr Chin has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received research grants from Janssen Pharmaceutical Companies of Johnson & Johnson, the National Institutes of Health, Ironwood Pharmaceuticals, and SoniVie Ltd; has served on an advisory board for Bayer Healthcare (through UCSD) and Flowonix; has served as an adjudication committee member for Arena Pharmaceuticals; is Circulation associate editor for the American Heart Association; and has received consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson. Drs Doelberg and Mr. Martin are employees of Actelion Pharmaceuticals Ltd. Dr Perchenet is an employee of and in the past has held stock/stock options for Actelion Pharmaceuticals Ltd; and currently holds stock/stock options in the parent company Johnson & Johnson. Prof Galie is a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grant support and personal fees from Bayer Healthcare, Pfizer, GlaxoSmithKline, and Janssen Pharmaceutical Companies of Johnson & Johnson; and has received nonfinancial support from Janssen Pharmaceutical Companies of Johnson & Johnson. Funding Information: This study was funded by Actelion Pharmaceuticals, Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Medical writing support was provided by Laura Corbett of eluSCIdate Ltd (Meggen, Switzerland) and was funded by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson. Dr Chin has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received research grants from Janssen Pharmaceutical Companies of Johnson & Johnson, the National Institutes of Health, Ironwood Pharmaceuticals, and SoniVie Ltd; has served on an advisory board for Bayer Healthcare (through UCSD) and Flowonix; has served as an adjudication committee member for Arena Pharmaceuticals; is Circulation associate editor for the American Heart Association; and has received consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson. Drs Doelberg and Mr. Martin are employees of Actelion Pharmaceuticals Ltd. Dr Perchenet is an employee of and in the past has held stock/stock options for Actelion Pharmaceuticals Ltd; and currently holds stock/stock options in the parent company Johnson & Johnson. Prof Galie is a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grant support and personal fees from Bayer Healthcare, Pfizer, GlaxoSmithKline, and Janssen Pharmaceutical Companies of Johnson & Johnson; and has received nonfinancial support from Janssen Pharmaceutical Companies of Johnson & Johnson.
PY - 2022/2/22
Y1 - 2022/2/22
UR - http://www.scopus.com/inward/record.url?scp=85123983124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123983124&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.12.006
DO - 10.1016/j.jacc.2021.12.006
M3 - Letter
C2 - 35177202
AN - SCOPUS:85123983124
SN - 0735-1097
VL - 79
SP - e177
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 7
ER -